Pakistan’s pharmaceutical sector continues to surge, driven by rising healthcare demand, population growth, and a strategic push for domestic production. As of July 2025, the Pakistan Stock Exchange (PSX) showcases the top-performing pharma companies based on market capitalization, reflecting investor confidence and sectoral strength.
Top 10 Pharma Companies on PSX – July 2025
| Rank | Company Name | Market Capitalization (USD) |
|---|---|---|
| 1 | GlaxoSmithKline Pakistan (GLAXO) | $438 million |
| 2 | Abbott Laboratories Pakistan (ABOT) | $371 million |
| 3 | Haleon Pakistan Limited (HALEON) | $330 million |
| 4 | Highnoon Laboratories (HINOON) | $202 million |
| 5 | AGP Limited (AGP) | $189 million |
| 6 | The Searle Company (SEARL) | $167 million |
| 7 | Hoechst Pakistan Limited (HPL) | $105 million |
| 8 | Citi Pharma Limited (CPHL) | $66 million |
| 9 | Macter International (MACTER) | $62 million |
| 10 | Ferozsons Laboratories (FEROZ) | $60 million |
Export Growth and Sector Expansion
Pakistan’s pharmaceutical exports hit a two-decade high of 34% in FY25, reaching $457 million. This surge places pharma among the top five fastest-growing export categories, signaling global competitiveness and rising demand for locally manufactured medicines.
Investment and Innovation
Companies like Haleon and AGP are expanding production capacities, while Highnoon and Searle are investing in new product lines and R&D. Strategic partnerships and acquisitions are also reshaping the landscape, with firms targeting both domestic and international markets.
Investor Confidence
The consistent performance of these companies on the PSX reflects strong investor sentiment. With healthcare becoming a national priority, pharmaceutical stocks are increasingly viewed as resilient and growth-oriented assets.
+ There are no comments
Add yours